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Abstract
Cytokine/cytokine receptor gene polymorphisms related to structure/expression could impact immune response. Hence,
the 2237 polymorphic site in the 59 promoter region of the IL-12Rb2 (SNP ID: rs11810249) gene associated with the AP-4
transcription motif GAGCTG, was examined. Amplicons encompassing the polymorphism were generated from 46
pulmonary tuberculosis patients, 35 family contacts and 28 miscellaneous volunteers and sequenced. The C allele
predominated among patients, (93.4%, 43/46), and in all volunteers and contacts screened, but the T allele was exclusively
limited to patients, (6.5%, 3/46). The functional impact of this polymorphism on transcriptional activity was assessed by
Luciferase-reporter and electrophoretic mobility shift assays (EMSA). Luciferase-reporter assays showed a significant
reduction in transcriptional efficiency with T compared to C allele. The reduction in transcriptional efficiency with the T allele
construct (pGIL-12Rb2-T), in U-87MG, THP-1 and Jurkat cell lines, were 53, 37.6, and 49.8% respectively, compared to the C
allele construct (pGIL-12Rb2-C). Similarly, densitometric analysis of the EMSA assay showed reduced binding of the AP-4
transcription factor, to T compared to the C nucleotide probe. Reduced mRNA expression in all patients (3/3) harboring the
T allele was seen, whereas individuals with the C allele exhibited high mRNA expression (17/25; 68%, p=0.05). These
observations were in agreement with the in vitro assessment of the promoter activity by Luciferase-reporter and EMSA
assays. The reduced expression of IL-12Rb2 transcripts in 8 patients despite having the C allele was attributed to the
predominant over expression of the suppressors (IL-4 and GATA-3) and reduced expression of enhancers (IFN-a) of IL-12Rb2
transcripts. The 17 high IL-12Rb2 mRNA expressers had significantly elevated IFN-a mRNA levels compared to low
expressers and volunteers. Notwithstanding the presence of high levels of IL-12Rb2 mRNA in these patients elevated IFN-a
expression could modulate their immune responses to Mycobacterium tuberculosis.
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Introduction
Approximately 10% of the individuals, exposed to Mycobacterium
tuberculosis, develop clinical disease [1], the remaining individuals
are able to restrict, and eliminate the infection by generating an
appropriate immune response. Accumulating evidence suggests
that genetic factors contribute to variations in host response
against M. tuberculosis. Hence, the variety of cytokines expressed
during the incubation period critically influences the quality and
the dominance of the type of immune response, [2]. Therefore,
polymorphisms in cytokine genes and their receptors that could
potentially modify expression and or biological activity would be of
particular interest, [3]. Polymorphisms in the genes of cytokines
and their receptors have been reported to be associated with
tuberculosis disease status in various populations, [4].
Polymorphisms in the regulatory regions of the genes have been
associated with variation in gene expression, [5]. The present
study focuses on the investigation of the functional role of
polymorphism in the promoter region of the IL-12Rb2 gene. The
heterodimeric IL-12 receptor consists of IL-12Rb1 and b2
subunits. The b2 chain along with b1 chain constitutes the high
affinity IL-12 binding site. The effectiveness of IL-12 biological
function is determined by the presence of the IL-12 receptors on
the cells. Both receptor subunits bind IL-12; however the signal
transducing component is exclusively limited to the IL-12Rb2
chain, [6]. Further, the IL-12Rb2 chain is restricted in its
distribution among Th1 cells, [7,8]. Several transcription factors
such as SP-1, SP-3, NFATc2, GATA- 3, Oct-1, etc., regulate
expression of the IL-12Rb2 gene [9,10]. The alteration in the
promoter activity of IL-12Rb2 gene has been reported with the
base exchange at the following sites namely 21110, 21035,
2628, 2890 and 2465. Besides these sites, the polymorphism at
the 2237 position, (SNP ID: rs11810249) has been reported
previously in asthma [10]. As predicted by in silico analysis, the
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e343552237 polymorphic site is a part of the AP-4 transcription factor
binding motif. AP-4 is a ubiquitously expressed transcription
factor, which belongs to the basic helix-loop-helix leucine zipper
(hHLH-LZ) subgroup of bHLH proteins and recognizes the
symmetrical DNA core sequence CAGCTG [11]. This motif has
been referred throughout this manuscript as the consensus motif.
In the IL-12Rb2 promoter region the motif is predicted to be
located at position 2234 to 2239. This predicted cognate motif
has a conserved substitution at position 2234 C to G. This
sequence namely GAGCTG has been referred to as the IL-12Rb2
AP-4 motif. As the 2237 polymorphism is located in the
regulatory region, this may potentially modulate the IL-12Rb2
gene expression which in turn may influence the biological activity
of IL-12 required in the genesis of host immune response to M.
tuberculosis.
Apart from examining the role of the polymorphism at the
2237 site related to IL-12Rb2 mRNA expression, cytokines/
transcription factors that are known to be associated with
enhancement/suppression of IL-12Rb2 mRNA expression have
been investigated. The suppressors included were the cytokine IL-
4, [7] and the transcriptional factor GATA-3, [12]; and the
enhancer considered was IFN-a, [13].
Results
The one of the objectives of the present study was to detect the
presence of the 2237 C/T polymorphism (SNP ID: rs11810249)
in the IL-12Rb2 promoter region and to assess its distribution
among tuberculosis patients, household contacts and miscella-
neous healthy volunteers. For this purpose, we subjected the
622 bp DNA amplicons encompassing the polymorphic site,
derived from 109 individuals to double stranded DNA sequencing.
The results of this analysis are presented in Figure 1 & Table 1.
Examining the polymorphic position 2237 C/T, it was seen that
the C2237 site was present in 93.4% (43 / 46) patients and in all
contacts (35 / 35) & healthy volunteers (28 /28); whereas the
T2237 position, was detected exclusively in 3 of the 46 (6.5%)
tuberculosis patients.
Altered transcriptional activity
The substitution of T for C at the 2237 polymorphic site alters
the IL-12Rb2 AP-4 transcription factor binding motif GAGCTG,
[10,11,14]. Therefore to evaluate the impact of C to T
polymorphism on transcriptional efficiency, promoter-reporter
constructs harboring the polymorphic binding sites were trans-
fected into U-87MG, THP-1 and Jurkat cell lines, (Figure 2, Panel
A). Figure 2, Panel B, shows the estimated relative luciferase
activity with each of the constructs in the respective cell lines.
Luciferase reporter gene driven by IL-12Rb2 promoter containing
the C allele (pGIL-12Rb2-C) exhibited significantly higher
luciferase activity in all cell lines compared to the T allele
construct (pGIL-12Rb2-T). The maximum luciferase activity of
37.862.8 (Mean 6 SEM) fold over the promoter less PGL3-Basic
vector was observed in the Jurkat cell line with the construct pGIL-
12Rb2-C. This maximal activity was set as a reference value of
100%, and promoter activity of other constructs was compared
against this reference value. Accordingly, the activity of pGIL-
12Rb2-T in Jurkat cell line was observed to be 50.663.3%. While
the transcriptional activity of pGIL-12Rb2-C construct in THP-1
and U-87 MG cell lines was 50.764.9 and 17.260.3%, compared
to the pGIL-12Rb2-T construct wherein it was reduced to
31.862.4 and 8.160.4% respectively.
The luciferase activity of the pGIL-12Rb2-T construct was
lower in all the three cell lines investigated, (Figure 2, Panel B).
The observed reduction in luciferase activity with the T compared
to the C allele, in U-87MG, THP-1 and Jurkat cell lines was 52.7,
37.3 and 49.1% respectively. This reduction was statistically
Figure 1. PCR amplification and sequencing analysis chro-
matograms for the 2237C/T polymorphism. Panel (A & B):
Chromatogram showing the sequencing analysis of the 622 bp
amplicon derived from individual with polymorphic C (shown in panel
A), or T type alleles (shown in panel B) respectively. The presence of the
wild type 2237C and the polymorphic 2237T allele has been indicated
with (*).
doi:10.1371/journal.pone.0034355.g001
Table 1. The distribution of 2237 C/T polymorphism among
patients, healthy contacts and volunteers.
Subjects
a 2237 C/T
b
C
c T
d
N
e %
f N%
Patients
g 46 93.4 3 6.5
Contacts
h 35 100 0 0
Volunteers
i 28 100 0 0
a Subjects included in the study;
b Polymorphism position ;
c Individuals with C nucleotide at 2237 position;
d Individuals with T nucleotide at 2237 position ;
e Total number of individuals investigated;
f Percentage of individuals.
g pulmonary tuberculosis patients ;
h healthy patients contacts ;
i Healthy laboratory Volunteers.
doi:10.1371/journal.pone.0034355.t001
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MG; p=0.0097 for THP-1; p=0.0001 for Jurkat cell lines
respectively; Figure 2, Panel B). These results suggest the
association of T allele with reduced promoter activity.
C to T polymorphism alters AP-4 binding
In silico analysis, revealed that C to T polymorphism, which
caused a reduction in promoter activity, also abolishes the AP-4
binding to IL-12Rb2 AP-4 motif (GAGCTG). We employed
EMSA to assess, the consequence of this polymorphism on binding
of AP-4 transcription factor and the results are presented in
Figures 3, 4, 5.
To establish and confirm the binding of C and T ds-oligos with
the AP-4 transcription factor, the AP-4 consensus probe was used
as a positive control. The binding efficiencies of C, T and AP-4
type probes to the nuclear factor was assessed in the presence of
varying concentrations (0 to 100 molar excess) of the unlabeled ds-
oligos containing the AP-4 consensus motif (CAGCTG, Figure 3,
Panel A). All probes exhibited formation of a DNA-protein
complex with the nuclear extract derived from PMA–PHA
activated Jurkat cells, (Figure 3, Panel A, AP-4 probe Lanes 1–5;
C probe Lanes 6–10; T probe Lanes 11–15). These complexes
showed identical electrophoretic mobility suggesting the binding of
similar nuclear factor(s) to the probes. Excess of unlabeled ds-
oligos containing the consensus AP-4 binding motif could displace
the radio labeled AP-4 probe from the DNA-protein complex. A
similar displacement of the radio labeled C and T probes from
their respective DNA-protein complexes by unlabeled AP-4
consensus ds-oligos was observed. These results suggest the
specificity of the binding of the transcription factor AP-4, to the
radio labeled AP-4, C and T probes.
Densitometric analysis of the DNA-protein complexes was
carried out. The densitometric value of the AP-4 consensus probe-
protein complex (positive control) was set as 100%, (Figure 4,
Panel B, Lane 2). The analysis revealed comparable binding of
AP-4 transcription factor to the AP-4 consensus and C-probes.
Accordingly the degree of binding with C and T probes was
estimated to be 96.562.3, (Mean 6 SD, Lane 7) and 44.862.1%
(Lane 12) respectively. Displacement assays revealed that a 10
molar excess of AP-4 consensus ds-oligo was sufficient to displace
the T probe from the DNA-AP-4-protein complex. Whereas this
displacement could not be achieved by 100 molar excess of the
AP-4 ds-oligo in case of the AP-4 consensus or C probe complexes
(Figure 3, Panel B, Lanes 5 & 10). These results revealed that the
intensity of the DNA-protein complex with consensus AP-4
(100%) and C (96.5%) probes was comparable. However, the
intensity of this complex with the T probe (44.8%) was
approximately 2 fold lower (Figure 3, Panel B, Lanes 7 & 12).
No DNA-protein complex was detected when EMSA was
carried out with the T probe in the presence of 100 molar excess of
the unlabeled T or C ds-oligos (Figure 4, Panel A, Lane 9 & 10).
However, 100 molar excess of unlabeled C ds-oligo (Lane3) but
not T ds-oligo (Lane 4) could completely abolish the formation of
this complex with the C probe. Densitometric analysis revealed
that the T ds-oligo could abolish 90% binding of the C probe to
AP-4 protein, (Figure 4, Panel B, Lane 4), whereas C ds-oligo
could completely abolish the binding of the same factor with the T
probe, (Figure 4, Panel B, Lane 10). The formation of the complex
with T / C probe could not be abolished in the presence (1006
molar concentration) of nonspecific competitor containing CEBP-
a binding motif, (Figure 4, Panel A & B Lanes 6 & 12). These
results further confirm the binding of AP-4 to C and T probes and
the higher affinity of C compared to the T probe to AP-4
transcription factor.
In order, to identify the proteins binding to the polymorphic
site, super shift experiments were conducted using the wild-type
probe harboring the C nucleotide at 2237 position and the
polymorphic type probe harboring T, and nuclear extracts derived
from Jurkat cells, (Figure 5). As this site previously has been
predicted to bind AP-4 transcription factor, polyclonal antibody
directed against transcription factor AP-4 was used in the super
shift assay. Addition of antibody super shifted the labeled probe-
lysate complex, (Figure 5, Lanes 3, 6, 9) compared to the
complexes in the absence of the antibody, (Lanes 2, 5, 8). The
shifted DNA- protein complex was further super-shifted maximally
Figure 2. Schematic representation of the vector constructs
and the luciferase activity observed in different cell lines.
Panel A. Schematic representation of the promoter constructs, namely
pGIL-12Rb2-C (with C allele) and pGIL-12Rb2-T (with T allele) that have
been used for the luciferase reporter assays. The region extending from
2591 up to +55 of the 59 region the IL-12Rb2 promoter was cloned into
pGL3-Basic vector. The location of the polymorphic allele at 2237
positions has been underlined. The dotted box indicates the AP-4
binding motif in the IL-12Rb2 promoter. Panel B: The vector constructs
pGIL-12Rb2-C, pGIL-12Rb2-T and the pGL3-Basic vector (Negative
control) were co-transfected along with pRL-TK vector into U-87, THP-
1 and Jurkat cell lines as described in methods. The renilla activity
expressed by the pRL-TK vector was used to normalize the transfection
efficiency. The reporter gene Firefly luciferase activity was determined
for each sample in triplicates, 42 hours post transfection. The relative
luciferase activity was expressed as fold increase in the activity
compared to the promoter less pGL3-Basic vector and the results has
been shown as mean 6 SEM of three independent experiments.
Student’s t test with unequal variances was carried out to compare the
transcriptional efficiency (*) of the constructs, (*p=0.0031; **p=0.0097,
***p=0.0001).
doi:10.1371/journal.pone.0034355.g002
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consensus oligos as competitor. Panel (A): Shows the EMSA experiments carried out to assess the displacement of the probe complexed with
the protein in the presence of excess molar concentrations (10, 50 & 1006) of the unlabelled AP-4 oligonucleotide as indicated. The probe-protein
complex was generated using the labeled AP-4 consensus (Lanes 1–5), C (Lanes 6–10) and T probes (Lanes 11–15). Panel (B): The bar diagram shows
the densitometric profile of the autoradiograph depicted in Figure 2, Panel c. The labeled AP-4 consensus (Lanes 1–5), C probe (Lanes 6–10) and T
probe (Lanes 11–15) were incubated with the nuclear lysate. The bars represent the mean 6 SD of three experiments.
doi:10.1371/journal.pone.0034355.g003
Figure 4. EMSA experiments to assess binding ability and specificity of probes. Panel (A): Shows the EMSA experiments to evaluate the
specificity of the Oligo – Nuclear protein complex formed with the C and T probes. The Oligo–Nuclear protein complex was formed in the presence of
1006 excess molar concentration of the unlabelled competitors namely Self / Heterologous / AP-4 consensus / Non specific (CEBP-a, NS) oligos.
Panel (B): Bar diagram showing the densitometric profile of the autoradiograph, Figure 5.7, Panel A. The C & T type of oligo without nuclear lysate
(Lanes 1 & 7) ; with nuclear lysate and without competitors (Lanes 2 & 8); with self competitors (Lanes 3 & 9) ; with heterologous competitors (Lanes 4
& 10 ); with unlabelled AP-4 consensus oligo ( Lanes 5 & 11) and with unlabelled non specific oligo (NS, CEBP-a, Lanes 6 & 12). The bars represent the
mean 6 SD of three experiments.
doi:10.1371/journal.pone.0034355.g004
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type C probe (Lane 6) and the polymorphic type T probe (Lane 9).
As IL-12Rb2 surface expression was low in unstimulated
circulating PBMCs (Data not shown), experiments were carried
out to determine mRNA expression of the IL-12Rb2 subunit at
the baseline level in peripheral blood leucocytes derived from 28
tuberculosis patients, (Figure 6). Analysis was carried out to
establish a relationship if any between the IL-12Rb2 mRNA
expression and the polymorphism at 2237 position of the IL-
12Rb2 promoter.
IL-12Rb2 mRNA expression
The Relative transcript level (
_DD Ct) was calculated after
normalization with the b-actin mRNA and expressed with respect
to that of healthy laboratory volunteers (N=28) as described [15].
Individuals were categorized as high expressers when the deduced
transcripts levels was .1, while individuals with transcripts levels
,1 were categorized as low expressers. The mRNA expression of
the 28 tuberculosis patients, investigated showed a mixed
expression profile of the IL-12Rb2 mRNA expression, (Figure 6).
The mRNA expression in 3 patients harboring the T allele at
the 2237 position was low, (,1; Figure 6, Patient numbers 3, 5 &
7 respectively). The remaining 25 patients harboring the C allele
showed divergent expression of mRNA. 17 patients showed high
levels of expression (.1; 68%) and the 8 patients showed low
expression (,1; 32%). The high levels of expression of mRNA in
the presence of C allele in 17 patients and the low levels of mRNA
with the T allele in 3 individuals correlated with the in vitro
functional assays related to promoter activity as observed in the
luciferase reporter assays, (p=0.05 ; Fisher’s exact test). Similarly,
the EMSA assays also confirmed the higher binding of the AP-4
transcription factor with the C type allele compared to the T allele.
Assessment of IL-4, IFN-a and GATA-3 mRNA expression
In case of the 8 patients the IL-12Rb2 mRNA expression was
negligible despite their harboring C in the IL-12Rb2 AP-4 motif,
which was in contradiction to the high transcriptional activity
expected as determined by the reporter assay, (Figure 2). In this
regard, experiments were designed to investigate if any, the
possible role of additional modulators of IL-12Rb2 expression
such as IL-4, IFN-a and the master switch transcription factor
GATA-3. IL-4 and GATA-3 suppresses, whereas IFN-a is a
potent enhancer of IL-12Rb2 expression, [7,12,13].
The results of IL-4, GATA-3 and IFN-a mRNA expression
among the 28 untreated tuberculosis patients and equivalent
number of healthy volunteers have been depicted in figure 7.
These patients have been categorized based on the levels of IL-
12Rb2 mRNA detected, into 17 high and 11 low expressers as
described in Figure 6. In addition, the 11 low expressers were
further sub-divided into 8 patients with the C allele (Low-C) and 3
with the T allele (Low-T) in the IL-12Rb2 AP-4 motif.
As a group healthy volunteers had lower transcript levels for all
the three target genes investigated compared to tuberculosis
patients, (IL-4, p=0.03; IFN-a, p=0.009 and GATA-3, p=0.04).
On the other hand, differences between the patient groups were
seen. The 8 low expressers of IL-12Rb2 mRNA (Low-C) had the
highest transcript levels of IL-4 compared to the Low-T, (p=0.01)
& High-C (p=0.02) group of tuberculosis patients and healthy
volunteers examined, (p=0.002, Figure 7, Panel A). On
comparing the IFN-a transcripts, the Low-C patients had reduced
transcript levels compared to the Low-T and High-C patient
groups, (p=0.04, Figure 7, Panel B). The highest GATA-3
transcript levels was seen among the Low-C compared to Low-T
(p=0.05) & High-C patients, besides healthy volunteers (p=0.02,
Panel C).
Patients with the T mutation (Low-T), showed low expression of
IL-4 transcripts compared to Low-C (p=0.01) & High-C (p=0.02)
patient groups and healthy volunteers, (Figure 7, Panel A). These
patients showed higher IFN-a transcript’s compared to Low-C &
healthy volunteers and lower GATA-3 transcripts compared to
Low-C, (p=0.05) & High-C patients and healthy volunteers.
Discussion
This is the first report of the analysis of the polymorphism
2237C to T in the IL-12Rb2 gene and its association with
tuberculosis. We found the presence of the T nucleotide at 2237
position (SNP ID: rs11810249) of the IL-12Rb2 promoter
exclusively in patients. Since the C/T2237 polymorphic site, lies
on the putative AP-4 binding site, we investigated whether the
difference in the IL-12 receptor expression is due to the variation
in promoter activity owing to its differential binding. In silico
analysis predicted the loss of the binding of the AP-4 transcription
factor with C to T base exchange. The regulatory role played by
the polymorphism namely C/T at the 2237 position has been
confirmed by luciferase reporter assays, wherein we found that the
promoter construct with the C nucleotide had higher promoter
activity compared to the T nucleotide promoter construct. In
addition, the binding ability of C or T type probes with the AP-4
transcription factor was assessed by EMSA and super shift assays.
The results showed that the C type of probe had greater affinity to
bind the AP-4 transcription factor compared to the T type probe.
Figure 5. Supershift assay using AP-4 consensus, wild type and
polymorphic type probe incubated with / without AP-4
polyclonal antibody. The assay carried out utilizing different probes
without nuclear lysate ; (lanes 1 , 4 & 7); with Jurkat nuclear lysate ;
(Lanes 2,5 & 8) Super shift assay with Jurkat cell nuclear extracts was
carried out using anti AP-4 antibody (20 ml ) with specific AP- 4 probe
(lane 3), C and T type probes, lanes 6 & 9 respectively. The arrow head
indicates the shifted band corresponding to the different type of
probes. The star symbol indicates supershifted complex corresponding
to different probes. These data are representative of 2 independent
experiments.
doi:10.1371/journal.pone.0034355.g005
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assessed by the luciferase reporter assays. In addition to in vitro
assays, mRNA expression data showed that individuals with T
allele had the lowest expression of mRNA compared to other
counterparts. Hence polymorphism of C/T at 2237 position
could potentially affect the expression of the IL-12Rb2 receptor
component of the IL-12 receptor.
The factors that determine resistance or susceptibility to
tuberculosis remain ill-defined, [2]. Polymorphisms both in the
regulatory and coding region of the IL-12Rb2 gene have been
identified in leprosy, (21047delT, 21035A/G, 21033T.C,
–1023A/G, 2650delG, 2568A/C, 2557T/C, 2550T/C,
2464A/G 2464A/C, 202T/C and2188A/C, [16] and in
allergic, respiratory disorders such as asthma, (21035A/G,
21033T/C, 21023A/G, 2465A/G and 2237C/T, [10].
Alterations in the promoter activity, associated with polymorphism
in the genes of several cytokines and their receptors in tuberculosis,
[17,18] and other diseases have been examined, [19,20].
In the present study, analysis of the polymorphic site showed
that the T allele was found in 6.5% (3/46) and the C allele in
93.4% (43/46) of patients. Earlier reports on 2237 polymorphism
among Caucasoid asthmatics, the frequency of the T type allele in
asthmatics was low (2.5%, 2/80) compared to the C allele.
However in the study the distribution of 2237 C/T in healthy
controls and its functional consequence was not investigated, [10].
Mutations such as +1577A to G, and +2799 A to G and the
truncated +2496 del 91, in the coding region of the IL-12Rb2
gene, have been associated with reduced IFN-c production, [21].
As assessed by cross-competition experiments, the binding
affinity to the protein(s) by the wild-type C allele variant was
approximately 2-fold greater than that seen with the mutant T
allele counterpart. The reduction in transcriptional efficiency in U-
87MG, THP-1 and Jurkat cell lines was 53, 37.6 and 49.8%
respectively. These results indicated the influential role played by
the C/T nucleotide at 2237 position for promoter activity of the
IL-12Rb2 gene. The reduction in the promoter activity with the T
allele was not tissue specific, however, the degree of reduction was
tissue specific, where it was least reduced in THP-1 cell line. The
highest transcriptional activity of the constructs (pGIL-12Rb2-C
and pGIL-12Rb2-T) was observed in the Jurkat cell line followed
by THP-1 and least in U-87MG cell line. The highest activity
observed in Jurkat cells (human T cell lymphoma) may be due to
the fact that expression of IL-12Rb2 is primarily associated with
Th1 type of T cells, [8,22]. We predict that the higher activity of
the promoter with the C allele and reduced activity with the T
allele was due to the alteration in the binding of the transcription
factor AP-4.
Super shift experiments confirmed the binding of AP-4 to the
probes with C/T nucleotide at the 2237 position. The probe-
protein complexes formed with C/T probes migrated to the
position identical to that seen with AP-4 consensus sequence.
Complexes were further displaced upon addition of specific
polyclonal antibodies. As the T allele showed comparatively less
intensive binding as well as decreased transcriptional activity, it
appears, in vitro AP-4 seems to function as an activator, in the IL-
12Rb2 promoter. The change, in the AP-4 protein binding affinity
at this polymorphic site, could be potentially responsible, for the
alteration, in the in vivo expression of the IL-12Rb2 gene.
AP-4 has been described previously as an activator [14] as well
as a repressor of gene transcription, [23,24] indicating its probable
Figure 6. Relative mRNA quantification of IL-12Rb2 mRNA expression in tuberculosis patients (N=28). Histogram shows the IL-12Rb2
mRNA expression profile in the blood of the tuberculosis patients. The identification of the polymorphism at 2237 site has been carried out by PCR
amplification and sequencing (forward & reverse) of the 622 bp region spanning 2780 to 2159. The patients with the T at 2237 polymorphic site
has been indicated. The bars represent expression of IL-12Rb2 mRNA in each individual. The fold activity pattern in real time PCR assay was calculated
as described in methods, [15]. The individuals with reduced / elevated IL-12Rb2 mRNA expression have been designated as Low expressers / High
expressers.
doi:10.1371/journal.pone.0034355.g006
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affecting the AP-4 binding has been assessed in Pin1 promoter with
relation to Alzheimer’s disease, where the role of AP-4 as a
transcriptional repressor has been reported in the context of G to
C base exchange, [25]. In contrast, the functional investigation of
the SNP at the AP-4 binding site at position 256 (T to C) in the
promoter of interferon-gamma receptor 1 (IFNcR1) gene in tuberculosis
patients and other ethnic groups, showed loss of promoter activity,
[18].
Role of potential GATA3 binding motifs present at positions
21035, 21110, 2890, 2628, and 2465 of the IL-12Rb2
promoter on transcriptional efficiency have been previously
assessed. The mutation at the 21035 site did not alter the
binding, whereas mutation at the 2465 position a threefold
increase in transcriptional efficiency was seen. When the non-
polymorphic GATA binding sites (2628, 2890, 21110) were
mutated no alteration in the transcriptional efficiency was seen
[10]. The role of the promoter polymorphisms in other cytokine
receptor genes, such as G-611A & T-56C of the IFNGR1 gene
showed no association with susceptibility to mycobacterial
infection, [18]. However, an association between IL-10 promoter
polymorphisms at 2819 and 2592 sites with elevated IL-10 levels
in pleural tuberculosis has been reported, [17].
In 17 patients who harbored the C allele (17 / 25; 68%, High-
C) high levels of IL-12Rb2 mRNA expression was detected. On
the other hand, despite the presence of C allele at the 2237 site in
8 patients (Low-C) reduced levels of IL-12Rb2 mRNA were
detected. Comparing the suppressors (IL-4, GATA-3) and
enhancer (IFN-a) of IL-12Rb2 expression in these individuals a
direct relationship was observed between the high and low
expression of IL-12Rb2 mRNA. In 17 patients, high transcripts of
IFN-a and low levels of IL-4 & GATA-3 transcripts was detected,
whereas in 8 patients with low levels of IL-12Rb2 expression (Low-
C), significantly high transcripts levels of IL-4 compared to all
other groups of patients and healthy volunteers was observed.
Besides high transcript levels of IL-4 & GATA-3 were detected, a
concomitant reduction in IFN-a mRNA was detected in these 8
individuals. GATA-3 is a known to inhibit of the differentiation of
TH1 lineage of T cells by suppressing the expression of the IL-
12Rb2 [12], whereas IFN-a inhibits GATA-3 expression, [26].
Hence, the appropriate conditions for IL-12Rb2 mRNA expres-
sion was prevalent among the 17 high expressers and was absent in
the 8 low expressers. Whereas the 3 patients (Low-T) with low
levels of IL-12Rb2 expression had equivalent transcript levels of
IFN-a and low levels of IL-4, a condition conducive for optimal
expression of IL-12Rb2. However these individuals failed to
express IL-12Rb2 owing to the presence of the polymorphic allele
T in the AP-4 motif.
Apart from IL-4 and GATA-3, other suppressors include IL-10
[17,27], TGF-b [28] and IL-17 [29]. Additionally, the presence of
stress indicators such as cortisols and prostaglandin E2 [30] could
contribute to the depression of IL-12Rb2 mRNA expression. High
levels of these cytokines [17,31] and corticosteroids [32] have been
detected in serum/at the disease foci of tuberculosis patients.
Further, in vitro, induction of IL-4 has been reported in patients
following exposure to mycobacterial antigens, [33]. Additionally,
Figure 7. Real -Time PCR analysis for transcripts of suppressers
(IL-4 and GATA-3) and enhancers (IFN-a) of IL-12Rb2 mRNA in
28 tuberculosis patients and healthy volunteers. The Box plots
represents the expression levels of IL-4 (Panel A), IFN-a (Panel B) and
GATA-3 (Panel C) mRNA expression among the untreated Tuberculosis
patients and healthy volunteers (HV), as estimated by Real-Time PCR.
The patients were categorized based on IL-12Rb2 mRNA levels detected
and the presence of C/T allele at the 2237 position, (Figure 6). Target
gene expression was normalized with b-actin gene expression. The data
has been calculated with the 2
2DCt formula, as described in methods.
The horizontal bar represents the median value for mRNA in each
group, the 25
th and 75
th percentile have been represented by the
boxes. The whiskers represent the maximum and minimum values of
the data, respectively. The data has been plotted on log10 scale. Low-C:
Low IL-12Rb2 mRNA expressers with allele C at 2237 position (N=8);
Low-T: Low IL-12Rb2 mRNA expressers with polymorphic allele T at
2237 position (N=3); High–C: High IL-12Rb2 mRNA expressers with
allele C at 2237 position (N=17); HV: Healthy volunteers free of
tuberculosis (N=28). To compare the transcript levels between groups,
non-parametric Mann-Whitney Test was applied. (*) - Significant
differences in transcript levels between compared groups have been
indicated. Panel A: Low-C Vs Low-T, p=0.01; Low-C Vs HV, p=0.002;
Low-C Vs High-C (?????) p=0.02; Low-T Vs High-C, p=0.02;Low-T Vs HV &
High-C Vs HV, not significant. Panel B: Low-C Vs High-C (????), p=0.04;
High-C Vs HV, p=0.002; Low-T Vs HV, p=0.05. Panel C: Low-C Vs Low-
T, p=0.05; Low-C Vs HV, p=0.02; High-C Vs HV, p=0.04; Low-C Vs High-
C, and Low-T Vs HV not significant.
doi:10.1371/journal.pone.0034355.g007
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source of IFN-a have been reported to be present in untreated
tuberculosis patients, [34] could account for the elevated IFN-a
transcripts detected in patients in the present study. IFN-a is
known to down regulate IFNGR1 receptor in infected macro-
phages, thus making macrophages intransient to IFN-c induced
activation, [35,36]. We have reported the down regulation of
IFNGR1 following infection with M. tuberculosis, [37]. Besides
down regulation of IFNGR1 receptor, IFN-a inhibits the synthesis
of the IL-12p40 subunit of the IL-12 cytokine by human antigen
presenting cells, [36]. Hence elevated levels of IFN-a could be a
pre-disposing factor for the onset of clinical tuberculosis despite its
potency to induce expression of IL-12Rb2 mRNA. Besides IFN-a,
IFN-c has been shown to upregulate the expression of IL-12Rb2,
[7,8]. Elevated levels of IFN-c have been reported in the disease
site [38] as well as in circulation among tuberculosis patients,
[33,34].
The higher expression of the IL-12Rb2 receptor in 17 patients
did not result in resistance to M. tuberculosis. The plausible reasons
could be that, the over expression of IL-12Rb2 has been reported
to sustain murine T regulatory (Treg) cells [39]. Higher levels of
FOXP3 mRNA have been observed in tuberculosis patients,
[40,41]. FOXP3 protein is expressed exclusively in Treg cells,
[42]. Increased transcription of IL-12Rb2 gene in patients could
result in increased expression of the IL-12Rb2 chain, in
CD4+Tregs. The genesis and prevalence of Treg cells could
initiate an inappropriate immune response(s) in patients leading to
progressive disease.
Low IL-12Rb1 expressing PBMCs has been detected in
tuberculosis patients, [28]. Hence lack of expression of the IL-
12Rb1 chain on immune-competent cells despite the presence of
IL-12Rb2 chain would result in impairment in the binding of IL-
12. As a consequence, would lead to the failure of the development
of functional dendritic and NK cells, and critically impact the host
immune response. However, both IL-12Rb1&b2 mRNA in
bronchoalveolar lavage have been detected in tuberculosis
patients, [43]. Besides the coordinated expression of both IL-
12Rb1&b2 chains and the availability of the composite IL-12R in
patients, yet another scenario exists wherein, the availability of IL-
12 appears to be limiting, [34]. No one factor appears to be
universal among the patients of tuberculosis that determines the
loss of IL-12 bio-activity. The combination of factors that appear
to be accountable for the disease is varied as the range of
individuals susceptible to M. tuberculosis.
Materials and Methods
Ethics statement
The institutional ethical committees of the All India Institute of
Medical Sciences (AIIMS), and Lala Ram Sarup Institute of
Tuberculosis and Respiratory Diseases, Mehrauli, New Delhi,
India, (LRS), approved the study. All individuals included in the
study were Informed about the study and written consent was
obtained from them.
Study subjects
A total of 109 individuals consisting of untreated pulmonary
tuberculosis patients who were sputum AFB positive (N=46;
Mean age: 31 years; 26 males and 20 females) registered in the
Out-patient Department (OPD) of the LRS hospital and healthy
family contacts of the patients (N=35; Mean age 31.8 years; 20
males and 15 females) who were related / closely associated with
the patients were included in the study. Miscellaneous healthy
laboratory volunteers (N=28; Mean age: 30 years; 18 males and
10 females) from Department of Biotechnology, AIIMS, were
included as controls. All patients underwent clinical examination,
chest X-ray, sputum microscopy for acid fast bacilli (AFB), and
routine laboratory tests. Diagnosis of tuberculosis was made on
the basis of clinical and radiological assessment and detection of
AFB in sputum. Scrutinizing clinical histories of patients, physical
examination, and laboratory investigations ruled out the
occurrence of concomitant intracellular infections, in the enrolled
individuals. All patients were human immunodeficiency virus
negative. The healthy family contacts and miscellaneous healthy
laboratory volunteers were screened for clinical signs of
tuberculosis and were radiologically examined; when warranted
on the basis of the symptoms, additional tests such as sputum
examination for AFB and erythrocyte sedimentation rate were
undertaken.
Genomic DNA isolation
DNA was extracted from 300 ml of acetate citrate dextrose
(ACD) collected blood by using Wizard Genomic DNA isolation
kit (Promega, MD, USA) according to the manufacturer’s
instructions. The PCR reaction mixture in a final volume of
20 ml contained, 16 PCR buffer, 200 mM dNTPs, 2.5 mM
MgCl2, 0.5 mM of each primer IL-12F-780 and IL-12R -159
with 1.0 U of Taq DNA polymerase (MBI Fermentas, Lithuania)
and 100 ng of genomic DNA as template. A negative control
without DNA was also included. Initial denaturation of the
reaction mixture at 95uC for 5 min, and 35 cycles of each
denaturation (94uC, 45 sec), annealing (62uC, 45 sec) extension
(72uC, 45 sec) and a final extension at 72uC for 10 min, was
carried out.
Detection of amplified products and sequencing analysis
The resulting PCR amplified products (622 bp) were analyzed
by agarose gel electrophoresis (1.5%) in the presence of 1 mg/ml of
ethidium bromide and visualized under UV-Illumination (Syn-
Gene, Gene Genius Bio Imaging System, UK). The amplified
DNA fragments from tuberculosis patients, household contacts
and healthy volunteers were purified from the gel using the Gel
extraction kit (Promega) according to the manufacturer’s instruc-
tions, and subjected to double stranded DNA sequencing to detect
the polymorphism. The nucleotide sequences were analyzed using
GeneDoc (Version 2.6.002 Nicholas and Nicholas 1997).
In silico analysis
The amplified 2591 to +55 region of the IL-12Rb2 promoter
fragment was analyzed for the presence of transcription factor
binding motifs, (http://motif.genome.jp).
Promoter–reporter constructs
Using DNA with CC genotype as template the 2591 to +55 59
flanking region of the IL-12Rb2 gene was PCR amplified utilizing
primers 2591F and +55R [9] (Table 2) and high fidelity proof
reading enzyme (Pfu DNA polymerase, MBI). To facilitate
cloning, SacI and NheI sites were incorporated in the forward
and reverse amplimers. The purified 646 bp amplicon was cloned
upstream to the luciferase reporter gene in pGL-3-Basic to
generate pGIL-12Rb2-C construct. To examine the role of C to T
polymorphism in the cognate AP-4 binding motif (GAGCTG)
present in the pGIL-12Rb2-C construct, it was changed to
GAGTTG by site directed mutagenesis to generate the pGIL-
12Rb2-T construct.
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The purified promoter reporter construct (pGIL-12Rb2-C)
harboring C nucleotide (wild type allele) at the polymorphic site
(2237) was used as a template for the site-directed mutagenesis.
For mutagenesis of the 2237 polymorphic site, the Quick-change
site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) and
the primers FTMU 59-attatgcagagttgccgacccct-39 and RTMU 59-
aggggtcggcaactctgcataat- 39 containing T nucleotide at the 2237
position were used. The resulting construct pGIL-12Rb2-T
obtained was used for transfection studies after confirming the
polymorphism by DNA sequencing.
Human Cell lines
Jurkat cells (T cell lymphoma, NCCS, India) and THP-1
(monocyte cell line, ATCC, USA) were cultured in RPMI-1640
(GIBCO) supplemented with 10% heat inactivated fetal bovine
serum (GIBCO) and antibiotics, (100 u/ml penicillin, 75 mg/ml
streptomycin, 50 mg/ml gentamycin) in a humidified, 5% CO2 air
atmosphere incubator, at 37uC. The U-87MG (glioblastoma,
ATCC, USA) cells were grown under identical conditions with
supplements in DMEM (Life Technologies).
Transfection and Luciferase Assays
1610
6 Jurkat/THP-1 cells/ml suspended in plain RPMI media
were co-transfected with the promoter reporter constructs (2 mg)
and renilla expression vector, pRL-TK (0.5 mg) using 7 mlo f
Lipofectamine (Invitrogen). Cells transfected with pGL3-Control
vector (SV-40 promoter, Promega) and promoter less vector
pGL3-Basic, served as positive, and negative controls, respectively.
The U-87MG cells were transfected as described [44]. Thirty-six
hours later, transfected cells were stimulated with PHA (1 mg/ml)
and PMA (50 ng/ml, Sigma) for five hours. Then the stimulated
cells were washed with cold PBS, lysed (Passive Lysis Buffer,
Promega) and centrifuged (10,500 g) for 10 min at 4uC. Firefly
and renilla luciferase activities in supernates were estimated
according to manufacturer’s protocol, (Dual Glo Luciferase assay
system, Promega; Sirius-Single Tube Luminometer, Berthold
Detection Systems, Australia). Transfection efficiency was nor-
malized based on the renilla luciferase activity. The normalized
firefly luciferase activity was expressed as fold increase over pGL3–
Basic.
Electrophoretic mobility shift assays (EMSA)
The change in the binding of the AP-4 transcription factor to its
motif with C/T being present was evaluated using EMSA. Sense
and anti-sense oligonucleotides (Table 2) extending from 2248 to
2224 containing the wild type (GAGCTG) or polymorphic
(GAGTTG) AP-4 binding motifs, were annealed and end labeled
([c-32 P] ATP, 3000 Ci mmol-1, BRIT, India), using T4
polynucleotide kinase, (Promega). The purified labeled probes
Table 2. List of primers used in the study.
Assay Name Sequence
Sequencing IL-12F-780 59 - agagcggttttaaggtaatgccca - 39 (622 bp )
a
IL-12R -159 59 - actcccgtataggtcccgtgtt - 39
Cloning 2591F
b 59- gcgcgagctcgatatctaaataaaatctct - 39 (646 bp)
+55R
c 59- agttccctgatggctgtcaaca- 39
Mutagenesis FTMU 59- attatgcagagttgccgacccct - 39
RTMU 59- aggggtcggcaactctgcataat - 39
EMSA C probe S 59- attatgcagagctgccgacccctct - 39
C probe AS 59- agaggggtcggcagctctgcataa t-39
T probe S 59- attatgcagagttgccgacccctct - 39
T probe AS 59- agaggggtcggcaactctgcataat -39
AP4-S 59- cacccggtcagctggccctacacc -39
AP4- AS 59- ggtgtagggccagctgaccgggtg -39
C/EBP-a S5 9- atgtttttatgtaataaaa -39
C/EBP-a AS 59- ttttattacataaaaacat -3 9
Real time Primers b-Actin –F 59- agaggggtcggcaactctgcataat -39 (101 bp )
b-Actin –R 59- atgctatcacctcccctgtgtg - 39
IL-12mRNA-F 59- cctgtatcaatagtgatgaaattc -39 (103 bp )
IL-12mRNA-R 59- tcccttctgtatgcaggataaat -39
IL-4RT-F 59- aacagcctcacagagcagaagac - 39 (101 bp )
IL-4RT-R 59- gccctgcagaaggtttcctt - 39
GATA3RT-F 59- gcgggctctatcacaaaatga -39 (7 9b p)
GATA3RT-R 59- gctctcctggctgcagac-39
IFNaRT- F 59- gctgaatgacctggaagcctgtg - 39 (169 bp )
IFNaRT-R 59- gatttctgctctgacaacctccc - 39
aAmplicon size.
bSacI site in bold incorporated in the 2591F primer.
cNheI site in bold incorporated in the +55R primer.
doi:10.1371/journal.pone.0034355.t002
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Jurkat T cells as described [45]. The protein content was estimated
by Bradford assay.
The nuclear extract containing 8.0 mg of protein was incubated,
with 0.5 mg non-specific oligo poly (dI-dC).poly (dI-dC) (Sigma) in
binding buffer (20% glycerol, 5 mM MgCl2, 2.5 mM EDTA,
2.5 mM DTT, 250 mM NaCl, 50 mM Tris–HCl, pH 7.5) for
10 min at 4uC in a final volume of 20 ml. Radiolabeled ds-DNA
fragments (40,000 cpm) in the presence or absence of unlabeled
probes were added to this mixture and incubated at 25uC for
25 min. The DNA–protein complexes were resolved on 5% non-
denaturing polyacrylamide gel (0.56TBE buffer at 4uC at 160 V),
autoradiography using a Kodak intensifying screen, scanned using
the Personal Molecular Imager (Bio-Rad, USA) and densitometric
analysis was done (Quantity-One program (Bio-Rad). To
determine the specificity, EMSA experiments were performed
with the known AP-4 consensus, [46] (positive) and nonspecific
(C/EBP-a, negative control) probes, [47].
Super shift assay
For the super shift analysis, the anti AP-4 antibody (5X,
Santacruz Biotechnology, CA, USA) was added to the nuclear
extract (8 mg) and incubated overnight at 4uC, Thereafter the
labeled AP-4, C & T probes were added and the complexes
formed were resolved and autoradiographed. The reaction
without antibody and without nuclear lysate was included as
control.
RNA isolation and cDNA synthesis
All RNA extractions were carried out using 1.5 ml blood sample
derived from the tuberculosis (N=28) patients and healthy
volunteers (N=28) using the RNeasy Blood Mini Kit (Qiagen
GmbH (Hilden, Germany) according to manufacturer’s instruc-
tions, with modification of an additional wash with Erythrocyte
Lysis buffer (EL buffer) and inclusion of on column DNAse
treatment Qiagen GmbH (Hilden, Germany). The RNA was
eluted in distilled DEPC-treated water and stored at 280uC. The
quality and quantity of the RNA was estimated by measuring the
OD at 260/ 280 nm and 260 nm using the Nanodrop (ND1000,
Nano Drop Technologies Inc. Wilmington, DE, USA). For reverse
transcription, DNA-free RNA (500 ng) from each sample was
mixed with 2 mM of Oligo-dT (100 mM stock) and DEPC-treated
water and denatured at 70uC for 10 min and immediately chilled,
in an ice bath. To this denatured mixture, reaction cocktail
containing, 16first strand buffer (56buffer), 1 mM DTT (10 mM
stock), 1 mM dNTPs (10 mM stock) and 8 U of RNAsin was
added. The mixture was incubated at 25uC for 10 min followed by
the addition of 200 U of Reverse Transcriptase (Promega). The
cocktail was incubated at 37uC for 90 min, after which the
Reverse Transcriptase was inactivated at 70uC for 10 min and the
resulting cDNA aliquots were stored at 280uC.
Real time PCR
The cDNA obtained was subjected to Real Time PCR analysis
using primer pairs for the IL-12Rb2 (IL-12mRNA-F and IL-
12mRNA-R), IL-4 (IL-4RTF and IL-4RTR) [48], IFN-a ( IFN-
aRTF and IFN-aRTR), GATA-3 (GATA-3F and GATA-3R),
[49] and for b-Actin (b Actin-F & b -Actin–R) genes respectively,
(Table 2). Intron flanking primers were designed for the IL-12Rb2,
IL-4 and GATA- 3 genes. PCR master reaction mix containing
Power SYBR Premix Ex Taq (Takara, Shiga, Japan), 0.5 mM
concentration of each primer (for b-actin, GATA-3, IFN-a) and
0.9 mM for IL-4. 100 ng of cDNA of each sample in optically clear
PCR tubes was set up. Real Time detection of transcripts was
carried out in MyIQ cycler (Bio-Rad, USA) using SYBR Green.
The cycling parameters for IL-12Rb2, IFN-a and b-actin was as
follows: denaturation at 95uC for 5 min; 40 cycles each of
denaturation at 95uC for 30 sec, annealing for 30 sec at 60uC and
extension at 72uC for 45 sec. For IL-4 and GATA-3 the
parameters were identical except for the annealing and extension
temperatures which was 60uC and 66uC for 1 min in case of
GATA-3 and IL-4 respectively. The Ct values obtained were used
for further data interpretation. The melt curve was generated with
a ramp rate of 2% in order to enable the generation of the melt
curve.
Assessment of the IL-12Rb2 mRNA expression in tuberculosis
patients was carried out. Equivalent numbers of healthy volunteers
were also included, in order to obtain the relative quantification of
the mRNA expression of IL-12Rb2 gene. For the same purpose,
the normalized expression was calculated from the threshold cycle
values (Ct) normalized to b-actin Ct values (DCt=CtIL-
12Rb22Ctb-actin) Then DDCt for each target was calculated as
DCt patient – DCt healthy volunteers. The normalized expression
of IL-12Rb2 gene relative to healthy volunteers was calculated as
2- DD Ct, as described [15]. The graph was plotted relative to the
mRNA expression of the miscellaneous healthy laboratory
volunteers. For group analysis for the expression of the IL-4,
IFN-a and the GATA-3 the 2‘(2DCt) method as described was
used, [50,51].
Statistical analysis
STATA 9.2 was used (Statacorp 2003, College Station, USA).
Student’s t test with unequal variances was used to compare the
transcriptional efficiency. Non parametric Mann-Whitney test was
used to compare the differences in the mRNA expression between
the study groups using Prism 4.03 (Graph Pad Software Inc., San
Diego, CA). Fisher’s exact test was applied to establish the
relationship between the polymorphism in the promoter region
and its activity and/mRNA expression.
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